Allosteric Disulfide Bonds in Thrombosis and Thrombolysis

Total Page:16

File Type:pdf, Size:1020Kb

Allosteric Disulfide Bonds in Thrombosis and Thrombolysis Journal of Thrombosis and Haemostasis, 4: 2533–2541 REVIEW ARTICLE Allosteric disulfide bonds in thrombosis and thrombolysis V . M . C H E N * and P . J . H O G G * *Centre for Vascular Research, University of New South Wales, Sydney; and Children’s Cancer Institute Australia for Medical Research, Sydney, Australia To cite this article: Chen VM, Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost 2006; 4: 2533–41. most frequently acquired amino acid in eight of the 15 taxa Summary. Allosteric disulfide bonds control protein function studied. Other amino acids that have accrued are Met, His, Ser by mediating conformational change when they undergo and Phe, whereas Pro, Ala, Glu and Gly have been lost. reduction or oxidation. The known allosteric disulfide bonds Considering that disulfide bonds follow addition of Cys, this are characterized by a particular bond geometry, the )RHSta- analysis indicates that acquisition of these bonds is a relatively ple. A number of thrombosis and thrombolysis proteins contain recent evolutionary event. one or more disulfide bonds of this type. Tissue factor (TF) was the first hemostasis protein shown to be controlled by an Types and classification of disulfide bonds allosteric disulfide bond, the Cys186–Cys209 bond in the membrane-proximal fibronectin type III domain. TF exists in There are two general types of disulfide bond; structural and three forms on the cell surface: a cryptic form that is inert, a functional. The structural bonds, which are the majority, are coagulant form that rapidly binds factor VIIa to initiate involved in the folding of a protein and stabilize the tertiary coagulation, and a signaling form that binds FVIIa and cleaves structure. It is thought that they assist folding by decreasing the protease-activated receptor 2, which functions in inflamma- entropy of the unfolded form [4]. The functional disulfide tion, tumor progression and angiogenesis. Reduction and bonds are the catalytic and allosteric bonds. These disulfide oxidation of the Cys186–Cys209 disulfide bond is central to the bonds regulate protein function. transition between the three forms of TF. The redox state of the The catalytic bonds are the better characterized. Examples of bond appears to be controlled by protein disulfide isomerase these are the disulfide bonds in the active sites of oxidoreduc- and NO. Plasmin(ogen), vitronectin, glycoprotein 1ba,integrin tases, such as the thioredoxin family of proteins [5,6]. These b3 and thrombomodulin also contain )RHStaple disulfides, disulfide bonds cycle between reduced and oxidized configu- and there is circumstantial evidence that the function of these rations in coordination with a dithiol or disulfide in a protein proteins may involve cleavage/formation of these disulfide substrate, resulting in reduction, formation or isomerization of bonds. a disulfide in the substrate. The allosteric bonds have only recently been identified [7]. These bonds control protein Keywords: glycoprotein 1ba,integrinb3, plasminogen, thrombo- function by triggering a conformational change when they modulin, tissue factor, vitronectin. break and/or form and are the subject of this review. A disulfide bond can be described in terms of the five Introduction dihedral or v angles that make up the bond. A dihedral angle is the angle of rotation about a certain bond, and is defined using Protein disulfide bonds are covalent links between two Cys four atoms [8]. v1 is the dihedral angle about the Ca–Cb bond, residues in the polypeptide chain. It appears that all life-forms v2 about the Cb–Sc bond, v3 about the Sc–Sc¢ bond, v2¢ about make this bond. Mammalian cells, for instance, make about the Sc¢–Cb¢ bond and v1¢ about the Cb¢–Ca¢ bond. These five 3000 different proteins that contain disulfide bonds. angles can be used to estimate the potential energy of a disulfide Addition of disulfide bonds to proteins is a major mechan- bond, which is called the dihedral strain energy (DSE) [8–10]. ism by which proteins have evolved and are still evolving [1–3]. The DSE is a semiquantitative measure, as it does not factor in Analysis of the trend in amino gain and loss in protein bond lengths and van der Waals contacts, for example, but has evolution has shown that Cys residues have accrued in 15 taxa been shown experimentally to reflect the amount of strain in a representing all three domains of life [3]. Moreover, Cys was the disulfide bond [11–14]. There are three basic disulfide bond configurations, based on Correspondence: Philip J. Hogg, Centre for Vascular Research, the sign of the v2, v3 and v2¢ angles; the spirals, hooks or staples University of New South Wales, Sydney NSW 2052, Australia. [15]. If the v3 angle is positive, then the bond is right-handed; if Tel.: +61 2 9385 1004; fax: +61 2 9385 1389; e-mail: it is negative, the bond is left-handed. When the v1 and v1¢ [email protected] angles are considered, there are 20 possible disulfide bond Ó 2006 International Society on Thrombosis and Haemostasis 2534 V. M. Chen and P. J. Hogg configurations. All 20 disulfide bond geometries were identified likely mediator [20], although protein disulfide isomerase (PDI) in a dataset of 6874 unique disulfide bonds in X-ray structures has also been implicated [24]. [8]. The main structural disulfide bond is the )LHSpiral. A In this review, we will discuss the presence of allosteric quarter of the disulfide bonds in the dataset were )LHSpirals, disulfide bonds in proteins involved in thrombosis and and this group also had the lowest DSE. A striking finding thrombolysis, and evidence for control of some of these from this analysis was that nearly all the catalytic disulfide proteins by these bonds (Table 1). We will focus initially on bonds were of the +/)RHHook configuration, whereas all the tissue factor (TF), which is the best characterized example to known allosteric disulfide bonds fell into the )RHStaple group. date. Other proteins that will be discussed are plasmin(ogen), Both of these bond groups have a high and narrow DSE vitronectin, glycoprotein 1ba,integrinb3 and thrombo- distribution, which is consistent with their functional role. modulin. A defining feature of the )RHStaple group is the short distance between the a carbon atoms of the disulfide bond. Tissue factor )RHStaple bonds have a mean Ca–Ca¢ distance of 4.3 A˚ , compared to a mean of 5.6 A˚ for all disulfide bonds [8]. This The blood coagulation process is initiated when the circulating short Ca–Ca¢ distance results from the fact that )RHStaples serine protease, factor (F) VIIa, forms a complex with its mostly link adjacent strands in the same antiparallel b-sheet cofactor, membrane-bound TF, to activate FVII, FX and FIX [7,16]. The strands need to pucker to accommodate the by limited proteolysis. Ternary TF–FVIIa–FXa or binary disulfide bond, and the associated deformation of the b-sheet TF–FVIIa complexes also signal through cleavage of protease- imparts a high torsional energy on the bond. A number of activated receptor 2 (PAR2) to control inflammation, tumor )RHStaple disulfide bonds have been shown to be involved in progression and angiogenesis. TF is a transmembrane glyco- the function of the protein in which they reside. The best protein with structural homology to the class II cytokine characterized are the )RHStaple disulfide bonds in the superfamily. It consists of two fibronectin type III domains, bacterial proteins botulinum neurotoxins [16,17], PapD [18] each with a disulfide bond. and DsbD [19], and the mammalian immune and human Analysis of 16 X-ray TF structures indicated that the immunodeficiency virus (HIV) receptor CD4 [20,21]. The viral N-terminal domain Cys49–Cys57 disulfide bond exists in one envelope glycoprotein, HIV gp120, also appears to be regulated of two configurations: a )RHSpiral or a +/)RHSpiral by cleavage of one or more of its four )RHStaple disulfide (Table 2, Fig. 1). Both configurations are subgroups of the bonds [16,22,23]. Analysis of the )RHStaple disulfide bonds in main structural disulfide bond, the )LHSpiral [8]. This type of nuclear magnetic resonance (NMR) structures indicates that disulfide bond is typical of immunoglobulin-like domains, of theyoftenswitchtothe)LHStaple configuration, which has an which the fibronectin type III domain is an example [25]. The even higher mean torsional energy and shorter mean Ca–Ca¢ disulfide bond links across the two sheets of the b-sandwich distance than the )RHStaple bonds (B. Schmidt and P. J. structure. The C-terminal domain Cys186–Cys209 disulfide Hogg, unpubl. obs.). The )LHStaple bonds, therefore, should bond exists exclusively as a )RHStaple in the 16 structures [26]. also be considered as potential allosteric disulfide bonds. In This bond has a higher DSE and a considerably shorter Ca– fact, it is an open question whether the )RHStaple or Ca¢ distance than the N-terminal RHSpiral (Table 2), which is )LHStaple configuration is the functional form in some in accordance with the typical features of these bonds [8]. The proteins. Cys186–Cys209 disulfide bond straddles the F and G strands of CD4 is a good example of how protein function can be the antiparallel b-sheet at a non-H-bonded site. The disulfide controlled by an allosteric )RHStaple disulfide bond. CD4 is a bond constrains a b hairpin turn adjacent to the stalk region class II cytokine receptor that is expressed on T cells. It is a coreceptor for binding of MHCII to the T-cell receptor and is the primary receptor for HIV. The extracellular part of CD4 Table 1 RHStaple disulfide bonds in selected thrombosis and thrombo- consists of a concatenation of four immunoglobulin-like lysis proteins domains, and the first, second and fourth domains contain a Protein Region Disulfide bond(s)* single disulfide bond.
Recommended publications
  • Hemoglobin Interaction with Gp1ba Induces Platelet Activation And
    ARTICLE Platelet Biology & its Disorders Hemoglobin interaction with GP1bα induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis Rashi Singhal,1,2,* Gowtham K. Annarapu,1,2,* Ankita Pandey,1 Sheetal Chawla,1 Amrita Ojha,1 Avinash Gupta,1 Miguel A. Cruz,3 Tulika Seth4 and Prasenjit Guchhait1 1Disease Biology Laboratory, Regional Centre for Biotechnology, National Capital Region, Biotech Science Cluster, Faridabad, India; 2Biotechnology Department, Manipal University, Manipal, Karnataka, India; 3Thrombosis Research Division, Baylor College of Medicine, Houston, TX, USA, and 4Hematology, All India Institute of Medical Sciences, New Delhi, India *RS and GKA contributed equally to this work. ABSTRACT Intravascular hemolysis increases the risk of hypercoagulation and thrombosis in hemolytic disorders. Our study shows a novel mechanism by which extracellular hemoglobin directly affects platelet activation. The binding of Hb to glycoprotein1bα activates platelets. Lower concentrations of Hb (0.37-3 mM) significantly increase the phos- phorylation of signaling adapter proteins, such as Lyn, PI3K, AKT, and ERK, and promote platelet aggregation in vitro. Higher concentrations of Hb (3-6 mM) activate the pro-apoptotic proteins Bak, Bax, cytochrome c, caspase-9 and caspase-3, and increase platelet clot formation. Increased plasma Hb activates platelets and promotes their apoptosis, and plays a crucial role in the pathogenesis of aggregation and development of the procoagulant state in hemolytic disorders. Furthermore, we show that in patients with paroxysmal nocturnal hemoglobinuria, a chronic hemolytic disease characterized by recurrent events of intravascular thrombosis and thromboembolism, it is the elevated plasma Hb or platelet surface bound Hb that positively correlates with platelet activation.
    [Show full text]
  • Common Gene Polymorphisms Associated with Thrombophilia
    Chapter 5 Common Gene Polymorphisms Associated with Thrombophilia Christos Yapijakis, Zoe Serefoglou and Constantinos Voumvourakis Additional information is available at the end of the chapter http://dx.doi.org/10.5772/61859 Abstract Genetic association studies have revealed a correlation between DNA variations in genes encoding factors of the hemostatic system and thrombosis-related disease. Certain var‐ iant alleles of these genes that affect either gene expression or function of encoded protein are known to be genetic risk factors for thrombophilia. The chapter presents the current genetics and molecular biology knowledge of the most important DNA polymorphisms in thrombosis-related genes encoding coagulation factor V (FV), coagulation factor II (FII), coagulation factor XII (FXII), coagulation factor XIII A1 subunit (FXIIIA1), 5,10- methylene tetrahydrofolate reductase (MTHFR), serpine1 (SERPINE1), angiotensin I-con‐ verting enzyme (ACE), angiotensinogen (AGT), integrin A2 (ITGA2), plasma carboxypeptidase B2 (CPB2), platelet glycoprotein Ib α polypeptide (GP1BA), thrombo‐ modulin (THBD) and protein Z (PROZ). The molecular detection methods of each DNA polymorphism is presented, in addition to the current knowledge regarding its influence on thrombophilia and related thrombotic events, including stroke, myocardial infarction, deep vein thrombosis, spontaneous abortion, etc. In addition, best thrombosis prevention strategies with a combination of genetic counseling and molecular testing are discussed. Keywords: Thrombophilia, coagulation
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supp Table 1.Pdf
    Upregulated genes in Hdac8 null cranial neural crest cells fold change Gene Symbol Gene Title 134.39 Stmn4 stathmin-like 4 46.05 Lhx1 LIM homeobox protein 1 31.45 Lect2 leukocyte cell-derived chemotaxin 2 31.09 Zfp108 zinc finger protein 108 27.74 0710007G10Rik RIKEN cDNA 0710007G10 gene 26.31 1700019O17Rik RIKEN cDNA 1700019O17 gene 25.72 Cyb561 Cytochrome b-561 25.35 Tsc22d1 TSC22 domain family, member 1 25.27 4921513I08Rik RIKEN cDNA 4921513I08 gene 24.58 Ofa oncofetal antigen 24.47 B230112I24Rik RIKEN cDNA B230112I24 gene 23.86 Uty ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 22.84 D8Ertd268e DNA segment, Chr 8, ERATO Doi 268, expressed 19.78 Dag1 Dystroglycan 1 19.74 Pkn1 protein kinase N1 18.64 Cts8 cathepsin 8 18.23 1500012D20Rik RIKEN cDNA 1500012D20 gene 18.09 Slc43a2 solute carrier family 43, member 2 17.17 Pcm1 Pericentriolar material 1 17.17 Prg2 proteoglycan 2, bone marrow 17.11 LOC671579 hypothetical protein LOC671579 17.11 Slco1a5 solute carrier organic anion transporter family, member 1a5 17.02 Fbxl7 F-box and leucine-rich repeat protein 7 17.02 Kcns2 K+ voltage-gated channel, subfamily S, 2 16.93 AW493845 Expressed sequence AW493845 16.12 1600014K23Rik RIKEN cDNA 1600014K23 gene 15.71 Cst8 cystatin 8 (cystatin-related epididymal spermatogenic) 15.68 4922502D21Rik RIKEN cDNA 4922502D21 gene 15.32 2810011L19Rik RIKEN cDNA 2810011L19 gene 15.08 Btbd9 BTB (POZ) domain containing 9 14.77 Hoxa11os homeo box A11, opposite strand transcript 14.74 Obp1a odorant binding protein Ia 14.72 ORF28 open reading
    [Show full text]
  • Investigating the Oligomerization of Vitronectin
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Masters Theses Graduate School 12-2008 Investigating the Oligomerization of Vitronectin Yacynth Ruwansara University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes Part of the Biology Commons Recommended Citation Ruwansara, Yacynth, "Investigating the Oligomerization of Vitronectin. " Master's Thesis, University of Tennessee, 2008. https://trace.tennessee.edu/utk_gradthes/483 This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a thesis written by Yacynth Ruwansara entitled "Investigating the Oligomerization of Vitronectin." I have examined the final electronic copy of this thesis for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Master of Science, with a major in Biochemistry and Cellular and Molecular Biology. Cynthia Peterson, Major Professor We have read this thesis and recommend its acceptance: Dan Roberts, Liz Howell Accepted for the Council: Carolyn R. Hodges Vice Provost and Dean of the Graduate School (Original signatures are on file with official studentecor r ds.) To the Graduate Council: I am submitting herewith a thesis written by Yacynth Ruwansara entitled “Investigating the Oligomerization of Vitronectin.” I have examined the final electronic copy of this thesis for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Master of Science, with a major in Biochemistry, Cellular and Molecular Biology.
    [Show full text]
  • Therapeutic Antibody-Like Immunoconjugates Against Tissue Factor with the Potential to Treat Angiogenesis-Dependent As Well As Macrophage-Associated Human Diseases
    antibodies Review Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases Zhiwei Hu ID Department of Surgery Division of Surgical Oncology, The James Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH 43210, USA; [email protected]; Tel.: +1-614-685-4606 Received: 10 October 2017; Accepted: 18 January 2018; Published: 23 January 2018 Abstract: Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well as macrophage-associated human diseases. Pathological angiogenesis, the formation of neovasculature, is involved in many clinically significant human diseases, notably cancer, age-related macular degeneration (AMD), endometriosis and rheumatoid arthritis (RA). Macrophage is involved in the progression of a variety of human diseases, such as atherosclerosis and viral infections (human immunodeficiency virus, HIV and Ebola). It is well documented that TF is selectively expressed on angiogenic vascular endothelial cells (VECs) in these pathological angiogenesis-dependent human diseases and on disease-associated macrophages. Under physiology condition, TF is not expressed by quiescent VECs and monocytes but is solely restricted on some cells (such as pericytes) that are located outside of blood circulation and the inner layer of blood vessel walls. Here, we summarize TF expression on angiogenic VECs, macrophages and other diseased cell types in these human diseases. In cancer, for example, the cancer cells also overexpress TF in solid cancers and leukemia. Moreover, our group recently reported that TF is also expressed by cancer-initiating stem cells (CSCs) and can serve as a novel oncotarget for eradication of CSCs without drug resistance.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • The Urokinase Receptor: a Multifunctional Receptor in Cancer Cell Biology
    International Journal of Molecular Sciences Review The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications Anna Li Santi 1,†, Filomena Napolitano 2,†, Nunzia Montuori 2 and Pia Ragno 1,* 1 Department of Chemistry and Biology, University of Salerno, Fisciano, 84084 Salerno, Italy; [email protected] 2 Department of Translational Medical Sciences, “Federico II” University, 80135 Naples, Italy; fi[email protected] (F.N.); [email protected] (N.M.) * Correspondence: [email protected] † Equal contribution. Abstract: Proteolysis is a key event in several biological processes; proteolysis must be tightly con- trolled because its improper activation leads to dramatic consequences. Deregulation of proteolytic activity characterizes many pathological conditions, including cancer. The plasminogen activation (PA) system plays a key role in cancer; it includes the serine-protease urokinase-type plasminogen activator (uPA). uPA binds to a specific cellular receptor (uPAR), which concentrates proteolytic activity at the cell surface, thus supporting cell migration. However, a large body of evidence clearly showed uPAR involvement in the biology of cancer cell independently of the proteolytic activity of its ligand. In this review we will first describe this multifunctional molecule and then we will discuss how uPAR can sustain most of cancer hallmarks, which represent the biological capabilities acquired during the multistep cancer development. Finally, we will illustrate the main data available in the literature on uPAR as a cancer biomarker and a molecular target in anti-cancer therapy. Citation: Li Santi, A.; Napolitano, F.; Montuori, N.; Ragno, P. The Keywords: urokinase receptor; uPAR; cancer hallmarks Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology.
    [Show full text]
  • Alternatively Spliced Tissue Factor Induces Angiogenesis Through Integrin Ligation
    Alternatively spliced tissue factor induces angiogenesis through integrin ligation Y. W. van den Berga, L. G. van den Hengela, H. R. Myersa, O. Ayachia, E. Jordanovab, W. Rufc, C. A. Spekd, P. H. Reitsmaa, V. Y. Bogdanove, and H. H. Versteega,1 aThe Einthoven Laboratory for Experimental Vascular Medicine and bDepartment of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands; cDepartment of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037; dCenter for Experimental and Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands; and eDivision of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, 3125 Eden Avenue, Cincinnati, OH 45267 Edited by Charles T. Esmon, Oklahoma Medical Research Foundation, Oklahoma City, OK, and approved September 25, 2009 (received for review May 15, 2009) The initiator of coagulation, full-length tissue factor (flTF), in complex pancreatic cancer cells transfected to express asTF produce more with factor VIIa, influences angiogenesis through PAR-2. Recently, an blood vessels (20), but it remained mechanistically unclear if and alternatively spliced variant of TF (asTF) was discovered, in which part how angiogenesis is regulated by asTF. One possibility is that asTF of the TF extracellular domain, the transmembrane, and cytoplasmic stimulates cancer cells to produce angiogenic factors, but it is also domains are replaced by a unique C terminus. Subcutaneous tumors plausible that asTF enhances angiogenesis via paracrine stimulation produced by asTF-secreting cells revealed increased angiogenesis, but of endothelial cells. Moreover, the role of VIIa, PAR-2 activation it remained unclear if and how angiogenesis is regulated by asTF.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]